MMM

3M Company (MMM) - Q2 2007 10-Q Summary

Business Context and Reporting Period

This filing covers the quarterly period ended June 30, 2007. 3M is a diversified global manufacturer organized into six operating segments: Industrial and Transportation, Health Care, Display and Graphics, Consumer and Office, Safety, Security and Protection Services, and Electro and Communications. Effective in the first quarter of 2007, the company reorganized its business segments to align better with markets and customers. The company completed the sale of its global branded pharmaceuticals business in Europe in January 2007 and the sale of its Opticom Priority Control Systems and Canoga Traffic Detection businesses in June 2007.

Key Financial Metrics

Material Changes vs. Prior Period

• Sales Growth: Worldwide sales increased 8.0% in Q2 2007 and 7.1% YTD. Local-currency sales growth was 9.3% in Q2, driven by organic volume growth of 6.5% and acquisitions of 2.8%. The sale of the branded pharmaceuticals business reduced reported sales growth by 3.8%.
• Profitability: Operating income increased 18.8% in Q2 and 37.5% YTD. Margins improved significantly due to gains on business sales, partially offset by restructuring and environmental charges.
• Unusual Items:
  • Gains on Sale: Q2 included a $68 million pre-tax gain from the sale of Opticom/Canoga businesses. YTD includes a $786 million pre-tax gain from the sale of the European pharmaceuticals business.
  • Restructuring: Q2 incurred $33 million in restructuring expenses, primarily related to the phase-out of a New Jersey roofing granule facility and other business-specific actions.
  • Environmental Liabilities: Q2 included a $13 million increase in environmental liabilities related to perfluorinated compounds (PFOA/PFOS) in Minnesota.
• Segment Performance: Health Care sales declined 1.1% due to the pharmaceutical divestiture, though non-pharmaceutical sales grew 23.1%. Safety, Security and Protection Services saw the highest sales growth at 20.7%.

Guidance, Outlook, and Risks

• Capital Allocation: The company utilized $2.9 billion for share repurchases and dividends in the first six months. A $7.0 billion two-year share repurchase authorization was approved in February 2007, with approximately $5.2 billion remaining as of June 30, 2007. The quarterly dividend was increased by 4.3% to $0.48 per share.
• Outlook: Management expects capital expenditures to total $1.4 to $1.5 billion for 2007. Stock-based compensation expense is expected to be $0.18 per diluted share in 2007.
• Risks and Contingencies:
  • Legal Proceedings: Significant ongoing litigation includes respirator mask/asbestos claims (approx. 13,870 pending claims) and environmental matters regarding PFOA/PFOS. The company increased environmental liability reserves by $121 million in Q1 and $13 million in Q2.
  • Market Conditions: Softness in the consumer electronics market and the residential construction market (specifically roofing granules) continues to impact certain segments.
  • Regulatory: Ongoing reviews by the EPA and international bodies regarding perfluorinated compounds.

Investor Verification Checklist

• Divestiture Impact: Verify the sustainability of earnings growth excluding the one-time $854 million pre-tax gain on the sale of pharmaceutical and traffic detection businesses.
• Environmental Reserves: Review the adequacy of the $149 million reserve for "Other environmental liabilities" and the potential for future increases related to PFOA/PFOS remediation in Minnesota and Alabama.
• Restructuring Progress: Monitor the completion of the $80 million accrued restructuring balance and the associated cash outflows.
• Segment Mix: Assess the long-term impact of the pharmaceutical divestiture on the Health Care segment's revenue base and margins.
• Debt Levels: Note the increase in total debt to $4.4 billion to fund share repurchases, though the debt-to-capital ratio remains at 30% with strong credit ratings (AA/Aa1).